Tesaro Inc. (Nasdaq: TSRO) reported that its chemotherapy induced nausea and vomiting treatment rolapitant failed to meet secondary endpoints in two Phase 3 studies. Shares of the biopharmaceutical plummeted $9.33 to close at $28.37.